Overview

Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Aims of Study: The aims of this study are 1) to examine the clinical utility of escitalopram in patients with major depression with atypical features; 2) to evaluate the tolerability of escitalopram in major depression with atypical features. Study hypothesis and objectives. This study is proposed as an open-label study to gather pilot data to examine whether escitalopram has clinical utility in the treatment of major depression with atypical features. Because of the exploratory nature of the design, no specific study hypotheses can be generated regarding efficacy of the drug. Our primary hypothesis is that the effect size of escitalopram in atypical depression will be similar to the effect size of escitalopram in major depression, its FDA approved indication.
Phase:
Phase 3
Details
Lead Sponsor:
Duke University
Collaborator:
Forest Laboratories
Treatments:
Citalopram
Dexetimide